Bank of America
MLNT

Bank of America’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bank of America’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,610
Closed -$1K – 7576
2019
Q4 		$1K Buy
1,610
+1,069
+198% +$2.59K ﹤0.01% 7022
2019
Q3 		$2K Sell
541
-19,673
-97% -$70.9K ﹤0.01% 7051
2019
Q2 		$134K Buy
20,214
+12,520
+163% +$47.7K ﹤0.01% 5845
2019
Q1 		$27K Buy
7,694
+2,854
+59% +$15.5K ﹤0.01% 6419
2018
Q4 		$19K Buy
4,840
+901
+23% +$11.5K ﹤0.01% 6502
2018
Q3 		$78K Buy
3,939
+2,539
+181% +$64.2K ﹤0.01% 6001
2018
Q2 		$45K Sell
1,400
-5,774
-80% -$208K ﹤0.01% 6205
2018
Q1 		$266K Sell
7,174
-593
-8% -$39K ﹤0.01% 5207
2017
Q4 		$614K Buy
+7,767
New +$575K ﹤0.01% 4803

Bank of America's MLNT Position: Q1 2020 in Review

Bank of America sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 1,610 shares — an estimated $1K sold.

Bank of America first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $614K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Bank of America reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Bank of America sold 1,610 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1K.
  • Bank of America first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Bank of America's Melinta Therapeutics, Inc. Common Stock position peaked at $614K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Bank of America's 13F filing for Q1 2020, filed 15 May 2020.